Biological agents in psoriatic arthritis
Anti-TNFα-therapy as an evidence-based treatment option for different clinical manifestations of psoriatic arthritis
M. Köhm1, H. Burkhardt2, F. Behrens3
- Rheumatology Department, Goethe-University Frankfurt am Main; and Fraunhofer IME, Projectgroup Translational Medicine and Pharmacology TMP at Goethe-University Frankfurt am Main, Germany.
- Rheumatology Department, Goethe-University Frankfurt am Main; and Fraunhofer IME, Projectgroup Translational Medicine and Pharmacology TMP at Goethe-University Frankfurt am Main, Germany.
- Rheumatology Department, Goethe-University Frankfurt am Main; and Fraunhofer IME, Projectgroup Translational Medicine and Pharmacology TMP at Goethe-University Frankfurt am Main, Germany. frank.behrens@ime.fraunhofer.de
CER8956
2015 Vol.33, N°5 ,Suppl.93
PI 0109, PF 0114
Biological agents in psoriatic arthritis
Free to view
(click on article PDF icon to read the article)
PMID: 26472504 [PubMed]
Received: 09/09/2015
Accepted : 09/09/2015
In Press: 15/10/2015
Published: 16/10/2015
Abstract
The development programmes of different TNF-blocking agents in psoriatic arthritis (PsA) not only provided substantial evidence for the therapeutic benefits of the specific treatment options, but also enabled new insights into the differential treatment effects on distinct disease manifestations. For the first time, specific robust evidence for distinctive effects on different manifestations of PsA, as a distinct entity separate from rheumatoid arthritis (RA), has been generated in a standardized way. The clearest evidence was shown for an effect on peripheral arthritis (polyarticular) with ACR20 response rates from 45 up to 58% (vs. 9-24% for placebo), and an inhibition of radiographic progression demonstrated for the first time for a treatment principle in PsA. However, as PsA does not remain confined to the peripheral joints, it was necessary to address diverse patterns of PsA-subtypes in the outcome measurements of the anti-TNF trials. Accordingly, the results of the clinical studies on anti-TNF treatment also have demonstrated efficacy on enthesitis, dactylitis and skin psoriasis, either in sub analysis of results from phase III RCTs, or in additional prospective studies.
